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Abstract 
  In the development of a component vaccine against caries, the catalytic region (CAT) and 
glucan-binding domain (GBD) of glucosyltransferase B (GtfB) from Streptococcus mutans 
have been employed as target antigens. These regions were adopted as primary targets 
because they theoretically include epitopes associated with enzyme function. However, their 
antigenicity has not been fully evaluated. Although there are many reports about successful 
vaccination using these components, the principle has not yet been put to practical use. For 
these reasons, we came to doubt the effectiveness of the epitopes in vaccine production and 
reevaluated the antigenic region of GtfB using in silico analyses combined with in vitro and in 
vivo experiments. The results suggest that the ca. 360-amino-acid variable region (VR) in the 
N-terminus of GtfB would be more reactive than CAT and GBD. This region is S. mutans- 
and/or GtfB-specific, non-conserved among other streptococcal Gtfs, and of unknown 
function. Immunization using an adenovirus vector-borne DNA vaccine confirmed that VR is 
an epitope that shows promise for the development of a caries vaccine.  
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Introduction 
  In spite of some success with preventive measures, dental caries continue to be prevalent 
and costly in many populations, and the development of a vaccine to prevent dental caries is 
still a desirable goal. Attempts to develop a vaccine against dental caries began with 
immunization using whole cells of the primary etiologic agent Streptococcus mutans in rhesus 
monkeys (23, 24). Although dental caries were successfully prevented in these studies, it was 
reported that the induced antibodies showed cross-reactivity with the human heart muscle (10, 
48). Thereafter, components derived from S. mutans were investigated to avoid induction of 
antibodies that cross-reacted with human tissue. The molecules primarily focused as target 
antigens are glucosyltransferase B (GtfB) (46) and antigen I/II (Ag I/II) (34).  
GtfB was further truncated and the catalytic region (CAT) (37) and the glucan-binding 
domain (GBD) (20) were employed as effective antigenic components. These components 
were combined with the cholera toxin B subunit (22), the saliva-binding region derived from 
Ag I/II (50), or both (30) to further enhance immunogenicity.  
Despite these successful results reported more than 10 years ago, a GtfB-based vaccine 
against caries has not yet been put to practical use. One reason may be that induction of 
mucosal immunity is needed to produce the effective secretory IgA (S-IgA) antibodies that 
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can prevent dental caries. Although encouraging results have been reported (3-6, 30, 38, 39), 
salivary S-IgA responses of are often variable, transient, and of low magnitude compared with 
serum IgG responses. Another cause for the delay of the anti-caries vaccine may be the 
antigenicity of the target antigens CAT and GBD, which were selected due to their association 
with enzyme function (40, 41). No study has addressed the immunogenicity of CAT and GBD 
by immunological, biochemical, or bioinformatic methods. It was recently suggested that 
effective screening for candidate vaccine antigens should include in silico analysis followed 
by in vitro and in vivo evaluation of antigenicity to reduce time and cost (29).  
In this study, we reevaluated the immunogenicity of GtfB using in silico approaches 
followed by in vitro and in vivo experiments to identify antigenic regions that may be 
employed in an effective anti-caries vaccine. On the basis of our findings, we constructed a 
DNA vaccine using an adenovirus vector and confirmed its ability to induce specific 
antibodies contributing to immunity in mice. 
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MATERALS AND METHODS 
  Bacterial strains and growth media. S. mutans MT8148 (serotype c) was routinely 
cultured in brain-heart infusion (BHI) broth (Difco Laboratories, Detroit, MI, USA) or on 
Mitis-Salivarius (MS) agar (Difco) at 37 °C in air. Escherichia coli XL-2 (Stratagene Ltd., 
Cambridge, UK) was cultured aerobically in Luria-Bertani (LB) medium. When appropriate, 
erythromycin, kanamycin, and ampicillin (Wako Pure Chemicals, Osaka, Japan) were added 
to the LB medium to final concentrations of 500, 30, and 100 µg/mL, respectively.  
  Preparation of GtfB. S. mutans MT8148 was cultured in 5 L of TTY medium (composed 
of Trypticase, tryptone, yeast extract, salts, and 1% glucose) instead of BHI broth, because of 
increased yield of bacterial cells (16) at 37 °C, to an optical density of 0.8 at 550 nm. The 
bacteria were collected by centrifugation, and cell-associated Gtf (CA-Gtf) was extracted by 
treatment with 50 mL of 8 M urea at 25 °C for 1 h. The extract was dialyzed against 10 mM 
sodium phosphate buffer (NaPB, pH 6.5) and adjusted to 60% saturation with ammonium 
sulfate. After centrifugation, the precipitate was dissolved in 10 mM NaPB (pH 7.5) and then 
dialyzed against the same buffer. The crude CA-Gtf sample was applied to a 
diethylaminoethyl (DEAE) Sepharose FF (GE Healthcare UK Ltd., Buckinghamshire, UK) 
column (bed vol., 10 mL) and eluted with a linear gradient of 0–1.0 M NaCl in the same 
6 
buffer. Active fractions measured as described below were pooled, concentrated by 
ammonium sulfate precipitation, dialyzed against 10 mM NaPB (pH 7.5), applied to a 
Bio-Scale CHT10-I column (bed vol., 10 mL; BioRad Laboratories, Hercules, CA, USA), and 
then eluted with a linear gradient of 10–500 mM potassium phosphate buffer (KPB) (15). To 
select the GtfB fractions, we performed a glucan synthesis assay (15), an enzyme-linked 
immunosorbent assay (ELISA) using anti-CA-Gtf antibody, and a western blot using 
anti-Gtf-I (GtfB) and anti-Gtf-SI (GtfC) monoclonal antibodies (47).  
  Glucan synthesis assay. Glucan-synthesizing activity was determined using 
[14C-glucose]-sucrose as described previously (15). In brief, reaction mixtures composed of 
Gtf and 10 mM [14C-glucose] sucrose (11.47 GBq/mmol) in 20 µL of 50 mM KPB (pH 6.0) 
were incubated for 1 h at 37 °C, spotted on a filter paper (1.0 × 1.5 cm), and air-dried. The 
filters were washed with methanol to remove non-incorporated [14C-glucose]-sucrose and 
then immersed in scintillation fluid to estimate the amount of de novo-synthesized 
[14C]-glucan.  
  Generation of anti-CA-Gtf antiserum. Antisera were prepared by repeatedly injecting 
rabbits intramuscularly with the emulsion made by mixing Gtf-active fractions that were 
purified using a DEAE Sepharose FF column and Freund’s complete adjuvant (Difco) once, 
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followed by Freund’s incomplete adjuvant (Difco) twice. The antibodies were purified from 
rabbit antiserum by 3× precipitation with 33% ammonium sulfate.  
  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting. Conventional SDS-PAGE and western blot analyses were carried out as described 
previously (12). In brief, Gtf samples and E. coli cells carrying the recombinant plasmid were 
suspended in SDS gel-loading buffer and boiled for 5 min. Proteins separated by SDS-PAGE 
were transferred onto a polyvinylidene fluoride (PVDF) membrane (Immobilon; Millipore, 
Billerica, MA, USA). After blocking with 5% bovine serum albumin (BSA), the membrane 
was reacted with a primary antibody at 37 °C for 1 h, and the bound antibody was 
subsequently detected using a solid-phase immunoassay employing goat anti-rabbit IgG 
antibody conjugated with alkaline phosphatase (AP), or goat anti-mouse IgG antibody 
conjugated with horseradish peroxidase (HRP).  
When NuPAGE® 4–12% Bis-Tris gels (Invitrogen by Life Technologies, Carlsbad, CA, 
USA) were used, the samples were suspended in NuPAGE® LDS sample buffer and 
NuPAGE® Sample Reducing Agent (Invitrogen) and incubated at 70 °C for 10 min. 
Coomassie brilliant blue (CBB) staining of the gels was performed using SimplyBlue 
SafeStainTM (Invitrogen). For immunoblotting, the proteins were transferred onto 0.2-μm 
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PVDF membranes (Invitrogen) for 30 min at a constant voltage of 200 V. After blocking with 
5% nonfat dry milk and 0.2% Tween 20 in Tris borate saline (TBS) at 4 °C overnight, the 
membranes were incubated with primary antibody in TBS containing 1% BSA at room 
temperature for 1 h. The membranes were washed 5 times with TBS containing 0.2% Tween 
and then incubated with secondary antibodies conjugated with HRP at a dilution of 1:3000 in 
TBS with 1% BSA at room temperature for 1 h. The membranes were then washed 5 times 
with TBS, and the signals were detected using a conventional solid-phase immunoassay.  
  ELISA. The ELISA was used to measure the amounts of GtfB or titers of antibody. The 
GtfB samples were applied to a 96-well plate, incubated at 37 °C for 1 h, and washed 5 times 
with phosphate buffered saline (PBS) containing 0.2% Tween 20 (PBST). The primary 
antibody at a dilution of 1:1000 in PBST was applied onto each well, and the plates were 
incubated at 37 °C for 1 h and then washed 5 times. The appropriate secondary antibody 
conjugated with AP at a dilution of 1:1000 was applied to each well and allowed to react at 
37 °C for 1 h, and the plates were then washed 5 times. Subsequently, the GtfB amount or 
antibody titer was assessed using an Alkaline Phosphatase Substrate Kit according to the 
manufacturer’s instructions (BioRad).  
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  Protein assay. The amounts of GtfB or protein in antiserum were estimated using a Pierce® 
BCA Protein Assay Kit according to the supplier’s manual (Takara Bio Inc., Shiga, Japan).   
  Polymerase chain reaction (PCR). All PCR analyses in this study were performed using 
TaKaRa EX Taq® Hot Start version (Takara) according to the manufacturer’s instructions as 
described previously (18). In brief, PCR was performed using 30 cycles of a denaturing step 
at 98 °C for 10 s and a primer-annealing and extension step at 60 °C for 30 s or 1 min 
according to the amplicon size.  
  Prediction of antigenic regions of GtfB in silico. The antigenic regions of GtfB were 
predicted using Kolaskar’s method (21) (available at http://imed.med.ucm.es/Tools/ 
antigenic.pl) or Parker’s method (33) and Welling’s method (49) using ANTHEPROT 2000 
version 6.0 software (7) (http://antheprot-pbil.ibcp.fr/index.php).  
  Preparation of recombinant CAT and GBD and generation of anti-CAT and anti-GBD 
antisera. Based on the result of Kolaskar’s method, PCR primers to amplify DNA fragments 
encoding CAT and GBD were designed (Table 1). The pSK6 plasmid that harbors the gtfB 
gene from S. mutans MT8148 (13) was used as a PCR template. Each amplified fragment was 
digested using the restriction enzymes that were added to the PCR primers and cloned into 
pGEX-6P-1 (GE Healthcare). The recombinant CAT and GBD were expressed as glutathione 
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S-transferase (GST) fusion proteins. These recombinant proteins were digested by passing 
through PreScission Protease (GE Healthcare), and their GST regions were removed using a 
GSTrap FF column (GE Healthcare). Recombinant proteins and the adjuvant were used to 
immunize the rabbits, and anti-CAT and anti-GBD antisera were obtained as described above.  
  Construction of DNA vaccine plasmid and variable region (VR) adenovirus. The VR 
region containing the antigenic regions predicted by Parker’s method was amplified by PCR 
using the pSK6 plasmid as a template and the primers shown in Table 1. The amplicon 
digested by KpnI and PstI was cloned into pSecTag2B (Invitrogen), and pSecTag2B-VRGB 
was constructed as the DNA vaccine plasmid for VR (Fig. 1 A). The expression cassette was 
cleaved by NruI and SphI from pSecTag2B-VRGB, blunted, and used to construct the 
recombined adenovirus according to a previous report (44). In brief, the blunted expression 
cassette was ligated with SwaI-digested pALC3 vector and introduced into E. coli DH10B 
using an in vitro phage packaging kit (Nippon Gene). The structure of the resulting cosmid, 
pALC3-VRGB, is illustrated in Figure 1B. To generate infectious recombinant adenoviral 
vectors, the pALC3-VRGB cosmid and pOG44 plasmid (Invitrogen) for the expression of 
FLP recombinase were cotransfected into HEK 293 cells (293 cell) seeded on a gelatin-coated 
well using Lipofectamine (GIBCO-BRL) according to the supplier’s instructions, and the 
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recombinant adenovirus AdV-VRGB was harvested after 15 days from wells in which 
bacteriolysis complement was observed (Figs. 1C and D). The titer of the harvested 
adenoviral suspension was measured using an Adeno-XTM Rapid Titer Kit (Takara).  
  Detecting the expression of AdV-VRGB-mediated gene and protein in 293 cells. Total 
RNA was extracted using TRIZOL® reagent (Invitrogen) from the 293 cells 3 days after they 
were infected with AdV-VRGB, and reverse transcription was performed using SuperScript 
III (Invitrogen) and Oligo (dT)20 primer (Invitrogen). To detect the mRNA of 
AdV-VRGB-mediated genes, we used primers to amplify the VR region (Table 1) and -actin 
primers (Invitrogen) as an internal control. In addition, total protein was extracted from the 
293 cells 3 days after AdV-VRGB infection and was assessed by western blotting and 
enhanced chemiluminescence.  
  Immunization with DNA vaccine for VR and generation of anti-VR antiserum. The 
DNA vaccine for VR was used to immunize 6 week old female mice (BALB/c AnNcrlCrlj; 
Charles River Laboratory Japan, Inc.) 4 times every night using retrograde intra-common 
ductal injections (43). The mice were injected with AdV-VRGB suspension (1 × 109 pfu in 
200 µL of lactated Ringer’s solution) the first time according to a previous report (43), and 
with 50 µg of pSecTag2B-VRGB plasmid in lactated Ringer’s solution the other 3 times. The 
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antiserum titer was measured by ELISA using 10 ng of the purified GtfB as an antigen, and 
serum was harvested from ascites 2 weeks after the last immunization.  
  Inhibition assay of GtfB activity by anti-VR antiserum. The effect of anti-VR antiserum 
on the GtfB was analyzed according to a previous method (11). A solution of purified GtfB 
(conc., 1.5 µg/µL) was incubated with an equal volume of anti-VR antiserum, anti-CA-Gtf 
antiserum, or sham serum undiluted or diluted 1:3 in PBS. The reaction mixtures of GtfB and 
serum were then incubated with [14C-glucose]-sucrose at 37 °C for 1 h, and the amount of 
[14C]-glucan was measured as described above. Triplicate samples were analyzed in this 
experiment. Significant differences were determined using Student’s t-test (p < 0.05).  
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RESULTS 
  Purification of GtfB. The cell-associated GtfB and GtfC enzymes were extracted from S. 
mutans MT8148 cells using 8 M urea, and were purified by DEAE-anion exchange 
chromatography and the following hydroxyapatite column chromatography (Fig. 2A and B). 
In DEAE-anion exchange chromatography, Gtf activity was observed in fractions 6–17, 
which were recovered as active fractions. During hydroxyapatite column chromatography, 
GtfB and GtfC were eluted in fractions 29 and 24, respectively. SDS-PAGE of GtfB and GtfC 
gave a single protein band with molecular masses of approximately 165 and 163 kDa, 
respectively (Fig. 2C). Anti-CA-Gtf antiserum reacted with both GtfB and GtfC (Fig. 2D), 
and anti-Gtf-I and anti-Gtf-SI antisera reacted with GtfB and GtfC, respectively (Figs. 2E and 
F). The anti-Gtf-I antiserum cross-reacted slightly with GtfC. The purified GtfB was used in 
further experiments.  
  Predicting antigenicity using Kolaskar’s method and the practical antigenicity of 
CAT and GBD derived from GtfB. As shown in Figure 3, primary catalytic and 
glucan-binding sites were included in the group of highly antigenic candidates. On the basis 
of this prediction, we designed PCR primers for CAT, such that the primer could amplify the 
region including primary and secondary catalytic sites. Likewise, the PCR primers for GBD 
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that could amplify the region including the 6 repeating units of GBD were designed. The 
CAT and GBD region fragments amplified by these PCR primers were ligated into 
pGEX-6P-1 to form pGEX-6P-1-CAT and pGEX-6P-1-GBD, respectively. The recombinant 
CAT and GBD were expressed as GST fusion protein, and the GST regions were removed 
from them by PreScission protease (Invitrogen). The recombinant CAT and GBD proteins 
were then used to immunize rabbits from which anti-CAT and anti-GBD antisera were 
obtained. The lysates from E. coli recombined with pGEX-6P-1, GEX-6P-1-CAT, and 
pGEX-6P-1-GBD were electrophoresed by SDS-PAGE and observed as 26, 38, and 72 kDa 
of GST fusion protein, respectively (Fig. 4A). In the western blot analyses used to evaluate 
the antigenicity of CAT and GBD, it was observed that anti-CA-Gtf antibody did not react 
with the CAT or GBD proteins (Fig. 4B) while anti-CAT and anti-GBD antisera reacted with 
the corresponding recombinant proteins, and the native GtfB served as a positive control (Figs. 
4C and D). In the inhibition assays of these antibodies (Fig. 5), anti-CAT and anti-GBD 
antibody were less able to inhibit GtfB activity than was anti-CA-Gtf antibody, although there 
was significant difference between the glucan synthesis inhibited by the anti-GBD antibody 
and the sham serum. Thus, it was suggested that CAT and GBD regions were not 
immunodominant compared with the other antigenic regions that reacted with anti-CA-Gtf 
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antibodies, although they were antigenic in rabbits.  
  Reevaluation of the antigenic region in GtfB using ANTHEPROT software. As it was 
suggested that CAT and GBD were non-immunodominant, we reevaluated the antigenic 
region of GtfB by the other in silico predictions identified by the Parker and Welling methods 
using the ANTHEPROT software (Fig. 6).  
According to these analyses, the antigenicity of the primary catalytic site was predicted to 
be low by both methods as this region was highly hydrophobic, lowly hydrophilic, and lowly 
solvent-accessible. On the other hand, the GBD region was also predicted to have relatively 
low antigenicity by both methods, although the 6 periodic antigenic peaks corresponding to 
the 6 repeating structures were identified as antigenic epitopes in Parker’s prediction. 
When GtfB was roughly divided into 3 parts, VR, CAT, and GBD, Parker’s prediction 
indicated that the N-terminal VR had more antigenic peaks and was more solvent-accessible 
than the other 2 parts. No report has evaluated the antigenicity of VR from GtfB. Thus, this 
region was adopted in the following experiments.  
  Expression of AdV-VRGB-mediated gene and protein in 293 cells. In the RT-PCR 
analysis used to confirm AdV-VRGB-mediated mRNA expression, appropriately 1.1-kbp 
fragment was amplified in the sample from the Adv-VRGB-infected 293 cells (Fig. 7A). 
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Western blot analysis was then used to confirm that the protein derived from AdV-VRGB was 
produced; an appropriate protein band with a molecular mass of approximately 46 kDa, 
including myc epitope and histidine tag derived from pSecTag2B was observed in the 
AdV-VRGB-infected 293 cells (Fig. 7C).  
  Immunization of mice with AdV-VRGB and pSecTag2B-VRGB. To induce the 
development of antibodies against VR, AdV-VRGB and pSecTag2B-VRGB were injected at 
the back of the hind legs of mice once and thrice, respectively. The reason why AdV-VRGB 
was not used for all 4 immunizations was to prevent the mice from dying due to the injection 
of adenovirus. To measure the titer of anti-VR IgG, ELISA using the purified GtfB as the 
antigen and goat anti-mouse IgG antibody as the secondary antibody was performed. It was 
observed that the titer of anti-VR IgG increased in 2 of 5 mice (Fig. 8). Thus, it was revealed 
that immunization with AdV-VRGB and pSecTag2B-VRGB could induce the development of 
antibody against VR. The antiserum against VR recovered from these 2 mice was pooled and 
used in further experiments.  
  Evaluation of the antiserum induced by DNA vaccine against VR. Reactivity of the 
antiserum induced by DNA vaccines against VR was evaluated by western blot analysis using 
crude CA-Gtf extracted from S. mutans cells using urea as an antigen (Fig. 9). The results 
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showed that the antiserum induced by DNA vaccines against VR reacted with natural GtfB. 
Thus, it was suggested that the VR of GtfB is the antigenic region and is more reactive than 
CAT and GBD.  
  Inhibition of GtfB activity by anti-VR antiserum. We carried out an inhibition assay to 
prove that the anti-VR antiserum from mice contains antibodies reacted with a native protein 
such as anti-CA-Gtf, and to evaluate the effect of anti-VR antiserum on the glucan synthesis 
of GtfB (Fig. 10). In this experiment, the protein concentration of each non-diluted anti-VR 
antiserum, anti-CA-Gtf antiserum, and sham serum was 60 µg/µL. When the ELISA using 
equal volumes of GtfB (conc., 1.5 µg/µL) was performed, the absorbance at 405 nm of the 
non-diluted anti-VR antiserum, anti-CA-Gtf antiserum, and sham serum was 1.2, 1.6, and 0, 
respectively. These results revealed that the anti-VR antiserum significantly inhibited GtfB 
activity compared with the sham serum. The anti-VR antiserum inhibited GtfB activity almost 
to the same degree, as did the anti-CA-GtfB antiserum when 60 µg protein of the antiserum 
was used. Thus, these results suggested that the anti-VR antiserum induced by AdV-VRGB 
and pSecTag2B-VRGB effectively inhibited GtfB activity.  
18 
DISCUSSION 
In the present study, we reevaluated the effectiveness of the CAT and GBD as epitopes in 
vaccine production and also found that the ca. 360-amino-acid VR, which exists at the 
N-terminus of GtfB, is a more reactive vaccine target.  
The large Gtf molecules hamper complete functional domain mapping. However, studies 
comparing the amino acid sequences of Gtf from various oral streptococci (Figure 6) have 
revealed that Gtf consists of 4 regions: an ca. 40-amino-acid conserved signal sequence; an ca. 
360-amino-acid VR with unknown function that is species-specific and not conserved among 
the other Gtfs; an ca. 500-amino-acid catalytic domain, which contains conserved amino acids 
that are necessary for sucrose hydrolysis (14, 25, 27); and a series of 6 direct repeats that 
function in glucan binding (1, 9, 28). The latter 2 functional domains were employed as 
potential vaccine target regions in previous attempts to develop a component vaccine against 
GtfB, owing to their association with enzyme function and the high degree of sequence 
conservation among streptococci. However, the antigenicity of those 2 regions was confirmed 
only by western blot analyses using antibodies induced by synthetic peptides corresponding to 
the CAT or GBD regions derived from GtfI of S. downei (40, 41). Thereafter, to make up for 
antigenicity, the diepitopic antigen consisting of both the CAT and GBD (45), the chimera of 
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CAT and the B subunit of cholera toxin (22), and the chimera of GBD and the saliva-binding 
region of Ag I/II (50) were applied. On the basis of these successful reports, we also tried to 
develop a DNA vaccine against CAT and GBD, but did not obtain the expected results. One 
result was that the recombinant CAT and GBD did not react with the antiserum induced by 
native Gtf from S. mutans (Fig. 4), although these recombinant proteins did induce antibodies 
that reacted with native GtfB and the corresponding recombinant proteins. In addition, the 
DNA vaccine plasmid for CAT and GBD using pcDNA3 did not mediate sufficient amounts 
of the recombinant proteins to induce specific antibodies, although expression of the objective 
mRNA was confirmed by RT-PCR in an in vitro experiment (data not shown). Thus, we 
began to doubt the antigenicity of these regions as a way to express antigenic protein and 
decided to focus on alternative domains.  
Secondary structure predictions suggest that the Gtfs are members of the α-amylase 
superfamily and contain a circularly permuted (/8-barrel motif (8, 19, 26). Our results in 
Figure 6 revealed that the primary CAT site (FDSIRVDAVDN) of GtfB was highly 
hydrophobic and its solvent accessibility was very low. Since these observations suggested 
that the primary CAT site would exist on the inside of the (/)8-barrel structure, it was 
thought that this region may be difficult to recognize as an antigen for the immune system, 
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although low-molecular-weight sucrose is able to pass through this structure as an enzyme 
substrate. Thus, it was suggested that the antigenicity of CAT would be low as shown by 
Parker’s prediction.  
In our previous study of glucosyltransferase from S. oralis (GtfR; 11), the incomplete 
recombinant GtfR without GBD reacted with the antiserum induced by native GTFR from S. 
oralis. An antiserum preliminarily prepared by immunization with the recombinant GtfR 
without GBD not only reacted with native GtfR in western blot analysis but also inhibited 
glucan synthesis by GtfR (data not shown). On the other hand, GbpA and GBD are 
homologous, and it was reported that immunization with the entire GbpA protein did not elicit 
a protective immune response (2, 36). Taken together, these observations indirectly suggested 
that GBD antigenicity would be lower than that of the other Gtf regions. Practically, our 
results suggested that GBD would not be immunodominant because few antigenic peaks were 
seen compared with the other GtfB regions according to analysis using Parker’s method 
(Figure 6).  
In this study, we reevaluated the antigenic GtfB region and tried to find a more potent 
antigenic component. Results of the in silico analysis using Parker’s method suggested that 
the VR derived from GtfB was immunodominant, as evidenced by its many antigenic peaks 
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compared with those of CAT and GBD (Fig. 6). As it was reported that the VR is specific to 
the Gtf of individual Streptococcus species (17, 18), our DNA vaccines would induce 
GtfB-specific antibodies that would have an effect only on S. mutans glucan synthesis and 
colonization, and would not interfere with Gtf-expressing members of the oral commensal 
microbiota.  
It was recently reported that non-immunodominant regions are effective as building blocks 
in a streptococcal fusion protein vaccine (42). Although CAT and GBD were suggested to be 
non-immunodominant in this study, they nevertheless may be attractive vaccine targets. Thus, 
fusion protein of VR and CAT or GBD may induce more effective antibodies to inhibit 
glucan synthesis of GtfB.  
We adopted the adenovirus vector that possesses an intensive promoter and a high 
infectious ability as a way to deliver recombinant antigen protein sufficient for mucosal 
immunization as well. Since it was demonstrated that AdV-VRGB expressed sufficient 
recombinant antigen protein to induce the development of antibodies that could inhibit GtfB 
activity in murine in vivo experiments, use of AdV-VRGB may also be effective in mucosal 
route immunization. As a natural consequence, AdV-VRGB ought to be applied to oral 
experiments in animals to test whether dental caries can be prevented. We realize that there is 
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a safety problem when it comes to application of this DNA vaccine virus. Even if it were safe, 
its use would not be permitted in the human oral cavity for dental caries prevention. Because 
of safety issues, we hesitated to use only DNA vaccine virus in all immunization steps; 
instead, we used DNA vaccine plasmid in the last 3 immunizations to reduce stress in the 
mice. We plan to use AdV-VRGB to make a hybridoma that produces anti-VR antibody to 
clone the gene encoding anti-VR antibody by phage display (35), and to transform this gene 
into a rice plant using Agrobacterium-mediated transformation (31, 32). Rice harvested in this 
planned study may be evaluated for passive immunization to prevent dental caries.  
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FIG. 1. Construction of DNA vaccine plasmid and adenovirus. The gene coding the variable 
region of gtfB was cloned into pSecTag2B and pSecTag2B-VRGB was constructed as a DNA 
vaccine plasmid for VRGB (A). The expression cassette of VRGB elicited from 
pSecTag2B-VRGB and pALC3 cosmid vector was ligated, packaged in  phage, and 
introduced into Escherichia coli. The cosmid obtained was pALC3-VRGB (B). 
pALC3-VRGB and pOG44, FLP recombinase expression plasmid, were cotransfected into 
293 cells and the infectious recombined adenovirus AdV-VRGB was harvested (C). 
Non-cotransfected 293 cells (NC) and cotransfected 293 cells 8 and 15 days after 
pALC3-VRGB and pOG44 cotransfection are shown (D).  
 
FIG. 2. Glucosyltransferase B (GtfB) purification from Streptococcus mutans MT8148. The 8 
M urea extraction from S. mutans cells was precipitated with 60% saturated ammonium 
sulfate and was applied onto a DEAE Sepharose FF column. Fractions 6–17 were collected as 
Gtf-active fractions (A). Gtf-active fractions were concentrated with ammonium sulfate 
precipitation and applied to a Bio-Scale CHT10-I column. The purified GtfB and GtfC were 
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eluted in fractions 29 and 24, respectively (B). Samples at each purification step were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (C) and assessed 
with western blotting analyses using anti-CA-Gtf (D), anti-Gtf-I (E), and anti-Gtf-SI (F) 
antisera. Lane M, molecular weight marker; 1, 8 M urea extraction; 2, precipitant of 1 by 
ammonium sulfate; 3, Gtf-active fraction eluted using a DEAE Sepharose column; 4, fraction 
29 eluted using a CHT10-I column; and 5, fraction 24 eluted using a CHT10-I column.  
 
FIG. 3. Glucosyltransferase B (GtfB) antigenicity prediction using Kolaskar’s method. 
Average antigenic propensity of the deduced GtfB amino acid sequence (1475 amino acid 
residues) was estimated (A), and the antigenic region sequences using Kolaskar’s methods are 
listed (B). The asterisks and brackets indicate the primary GtfB catalytic site and 
glucan-binding domain region, respectively.  
 
FIG. 4. Antigenicity evaluation of the recombinant catalytic region (CAT) and the 
glucan-binding domain (GBD). The recombinant CAT and GBD proteins were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (A), and their antigenicity was 
evaluated by western blotting analyses using anti-CA-Gtf (B), anti-CAT (C), and anti-GBD 
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(D) antisera. Lane M, molecular weight marker; 1, Escherichia coli lysate from 
pGEX-6P-1-CAT; 2, E. coli lysate from pGEX-6P-1-GBD; 3, recombinant glutathione 
S-transferase protein; and 4, Gtf-active fraction eluted using a DEAE Sepharose column.  
 
FIG. 5. Effect of anti-catalytic region (CAT) and anti-glucan binding domain (GBD) antisera 
on glucosyltransferase B (GtfB) activity. Purified GtfB (1.5 µg protein) reacted with 0, 20, or 
60 µg of protein of anti-CAT, anti-GBD, or anti-CA-Gtf antisera or sham serum at 37 °C for 1 
h was incubated with [14C-glucose]-sucrose at 37 °C for 1 h, and the amount of [14C]-glucan 
was measured. GtfB activity in non-serum was defined as 100%. Triplicate samples were 
analyzed in this experiment, and the asterisks indicate statistical significance by Student’s 
t-test (*, p < 0.01).  
 
FIG. 6. Glucosyltransferase B (GtfB) antigenicity prediction using ANTHEPROT software. 
The deduced GtfB amino acid sequence was evaluated for antigenicity using Parker’s method 
(A), hydrophobicity (B), Welling’s method (C), hydrophilicity (D), helical membranous 
regions (E), and solvent accessibility (F).  
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FIG. 7. Adv-VRGB-mediated mRNA and recombinant protein expression. Total RNA from 
AdV-VRGB-infected 293 cells was analyzed by reverse transcription polymerase chain 
reaction using the variable region (VR) primers shown in TABLE 1 (A) and -actin primer 
(B). Objective recombinant protein expression by the Adv-VRGB-infected 293 cells was 
assessed using western blotting analysis using anti-CA-Gtf antiserum (C). Lane M, molecular 
weight or DNA size marker; B, purified GtfB in Figure 2; 1, sample of 293 cells; 2, sample of 
293 cells transfected with pSecTag2B; 3, sample of 293 cells transfected with 
pSecTag2B-VRGB; 4, sample of 293 cells infected with non-combined adenovirus; and 5, 
sample of 293 cells infected with AdV-VRGB. The arrowheads indicate the band that reacted 
with anti-CA-Gtf antiserum.  
 
FIG. 8. Immunization of DNA vaccine for the variable region (VR). The DNA vaccine for VR, 
AdV-VRGB, and pSecTag2B-VRGB was intramuscularly injected into 5 mice according to 
the immunization schedule in the Materials and Methods section. Serum was obtained before 
4 immunizations and every 2 weeks after the last immunization. The serum titer was 
evaluated by measuring the absorbance at 405 nm in an enzyme-linked immunosorbent assay 
using purified glucosyltransferase B as an antigen.  
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FIG. 9. DNA vaccine-induced antiserum reactivity against the variable region (VR). The 
crude CA-Gtf that contained glucosyltransferase B (GtfB) was separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (A), and western blotting analyses with 
anti-CA-Gtf antiserum (B) and DNA vaccine-induced VR antiserum (C). Lane M, molecular 
weight marker and G, Gtf-active fraction eluted using a DEAE Sepharose column.  
 
FIG. 10. Effect of anti-variable region (VR) antiserum on glucosyltransferase B (GtfB) 
activity. Purified GtfB (1.5 µg protein) reacted with 0, 20, or 60 µg protein of anti-VR 
antiserum, anti-CA-Gtf antiserum, or sham serum at 37 °C for 1 h was incubated with 
[14C-glucose]-sucrose at 37 °C for 1 h, and the amount of [14C]-glucan was measured. The 
GtfB activity in the non-serum was defined as 100%. Triplicate samples were analyzed in this 
experiment, and the asterisks indicated statistical significance by Student’s t-test (*, p < 0.01; 








enzyme sitePrimer name 
CAT (1223–1521)   
GtfB/CAT-F 5′-TTAGGAATTCCTTATGGCTAACGATGTGG-3′ EcoRI 
GtfB/CAT-R 5′-CCGCTCGAGATCATATTGTCGCCATCATC-3′ XhoI 
GBD (3238–4431)   
GtfB/GBD-F 5′-GGTCGCGGATCCGTTTATTATCAACGAGTGG-3′ BamHI 
GtfB/GBD-R 5′-AGCGGGAATTCCATTAGTTAATCCGAAC-3′ EcoRI 
VR (115–1216)   
GtfB/VR-F 5′-GTTGGTACCGATTCTAATGAATCGAAATC-3′ KpnI 
GtfB/VR-R 5′-AACTGCAGTTCGTAACCGCCGATAG-3′ PstI 
The numbers in parentheses indicate the amplified nucleic acid position from the 5′ start of 
gtfB. The bold characters in the primer sequences indicate the added restriction enzyme site. 
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